AAPL   397.52 (+3.61%)
MSFT   215.27 (+0.75%)
FB   249.36 (+1.75%)
GOOGL   1,568.22 (+1.90%)
GE   6.70 (+0.15%)
TSLA   1,718.00 (+11.22%)
AMD   56.87 (+1.77%)
T   29.89 (-0.80%)
ACB   12.26 (+2.00%)
F   6.15 (+0.66%)
DIS   119.36 (+0.02%)
NFLX   566.39 (+3.22%)
BAC   24.09 (+0.29%)
BA   178.68 (+0.13%)
AAPL   397.52 (+3.61%)
MSFT   215.27 (+0.75%)
FB   249.36 (+1.75%)
GOOGL   1,568.22 (+1.90%)
GE   6.70 (+0.15%)
TSLA   1,718.00 (+11.22%)
AMD   56.87 (+1.77%)
T   29.89 (-0.80%)
ACB   12.26 (+2.00%)
F   6.15 (+0.66%)
DIS   119.36 (+0.02%)
NFLX   566.39 (+3.22%)
BAC   24.09 (+0.29%)
BA   178.68 (+0.13%)
AAPL   397.52 (+3.61%)
MSFT   215.27 (+0.75%)
FB   249.36 (+1.75%)
GOOGL   1,568.22 (+1.90%)
GE   6.70 (+0.15%)
TSLA   1,718.00 (+11.22%)
AMD   56.87 (+1.77%)
T   29.89 (-0.80%)
ACB   12.26 (+2.00%)
F   6.15 (+0.66%)
DIS   119.36 (+0.02%)
NFLX   566.39 (+3.22%)
BAC   24.09 (+0.29%)
BA   178.68 (+0.13%)
AAPL   397.52 (+3.61%)
MSFT   215.27 (+0.75%)
FB   249.36 (+1.75%)
GOOGL   1,568.22 (+1.90%)
GE   6.70 (+0.15%)
TSLA   1,718.00 (+11.22%)
AMD   56.87 (+1.77%)
T   29.89 (-0.80%)
ACB   12.26 (+2.00%)
F   6.15 (+0.66%)
DIS   119.36 (+0.02%)
NFLX   566.39 (+3.22%)
BAC   24.09 (+0.29%)
BA   178.68 (+0.13%)
Log in

NASDAQ:GLMDGalmed Pharmaceuticals Stock Price, Forecast & News

$4.57
+0.03 (+0.66 %)
(As of 07/13/2020 12:38 PM ET)
Add
Compare
Today's Range
$4.56
Now: $4.57
$4.62
50-Day Range
$4.75
MA: $5.10
$5.86
52-Week Range
$3.02
Now: $4.57
$7.38
Volume600 shs
Average Volume49,019 shs
Market Capitalization$96.47 million
P/E RatioN/A
Dividend YieldN/A
Beta2.51
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
Read More
Galmed Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.54 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLMD
CUSIPN/A
Phone972-3693-8448

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.04 million
Book Value$3.30 per share

Profitability

Net Income$-20,460,000.00

Miscellaneous

Employees17
Market Cap$96.47 million
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

How has Galmed Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Galmed Pharmaceuticals' stock was trading at $4.21 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GLMD stock has increased by 8.6% and is now trading at $4.57. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Galmed Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Galmed Pharmaceuticals.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Galmed Pharmaceuticals.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) released its quarterly earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.37) by $0.08. View Galmed Pharmaceuticals' earnings history.

What price target have analysts set for GLMD?

10 brokerages have issued 1 year target prices for Galmed Pharmaceuticals' shares. Their forecasts range from $8.00 to $33.00. On average, they anticipate Galmed Pharmaceuticals' share price to reach $20.22 in the next year. This suggests a possible upside of 342.5% from the stock's current price. View analysts' price targets for Galmed Pharmaceuticals.

Has Galmed Pharmaceuticals been receiving favorable news coverage?

News headlines about GLMD stock have trended very negative on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Galmed Pharmaceuticals earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Galmed Pharmaceuticals.

Who are some of Galmed Pharmaceuticals' key competitors?

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include Opko Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Rite Aid (RAD), TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL) and Immunomedics (IMMU).

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the following people:
  • Mr. Allen Baharaff, Co-Founder, CEO, Pres & Director (Age 55, Pay $784.86k)
  • Mr. Yohai Stenzler, CFO & Controller (Age 37, Pay $155.34k)
  • Mr. Guy Nehemya, Chief Operating Officer (Age 35, Pay $165.43k)
  • Dr. Liat Hayardeny, Chief Scientific Officer (Age 53, Pay $242.52k)
  • Dr. Tali Gorfine, Chief Medical Officer (Age 50, Pay $242.28k)

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $4.57.

How big of a company is Galmed Pharmaceuticals?

Galmed Pharmaceuticals has a market capitalization of $96.47 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-20,460,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is www.galmedpharma.com.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.